Загрузка...
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
Mutations of calreticulin (CALR) are detected in 25–30% of patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result in proteins with a novel C-terminal. We demonstrate that CALR mutations activated signal transducer and activator of transcription 5 (STA...
Сохранить в:
| Опубликовано в: : | Leukemia |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5420793/ https://ncbi.nlm.nih.gov/pubmed/27807369 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2016.308 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|